PPCB

Propanc Biopharma, Inc. operates as a biopharmaceutical company focused on developing novel cancer treatments based on pancreatic proenzymes. Headquartered in Melbourne, Australia, with operations in the United States, the company targets solid tumors through its proprietary enzyme-based therapies. Propanc's lead product candidate, PRP, is a formulation of trypsinogen and chymotrypsinogen designed to selectively target and eradicate cancer cells while sparing healthy tissue. The company's drug development strategy centers on addressing pancreatic, ovarian, and colorectal cancers, where current treatment options remain limited and prognosis is often poor. The company maintains a clinical-stage development model, advancing PRP through preclinical studies and regulatory pathways toward human trials. Propanc holds multiple patents covering its proenzyme technology platform across key markets including the United States, Europe, and Australia. As a development-stage enterprise, Propanc generates no commercial revenue and relies on capital raises to fund its research operations and clinical development activities. The company trades on the OTCQB market under the ticker symbol PPCB. Recent activities include optimizing its lead candidate's formulation, advancing intellectual property protection, and preparing regulatory submissions for clinical trial authorization. Propanc operates with a lean organizational structure typical of early-stage biotechnology companies, focusing resources primarily on research and development rather than commercial infrastructure.